The discussion happened before Trump’s nomination of Robert F. Kennedy Jr. to serve as HHS secretary, Dave Weldon for ...
In Uganda, women and girls are more affected by HIV. Out of 1.4 million people living with the disease, 860 000 are women and ...
2h
As the U.S. prepares to welcome a new presidential administration, leaders from business, public health, and community ...
Women - especially teen girls and young women living in sub-Saharan Africa - are disproportionately impacted by HIV globally, with about 3,100 acquiring HIV each week. They've also historically been ...
Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.
Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations ...
Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...
Merck, Bristol Myers and Gilead Sciences have all invested heavily in TIGIT, as have smaller biotechnology companies like ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.19 which represents a slight increase of $0.43 or 0.48% from the prior close of $89.76. The stock opened at $89 ...
Remdesivir plus dexamethasone vs dexamethasone alone reduces the risk of mortality among patients hospitalized with COVID-19.
Compared to the aggregate P/E ratio of 94.75 in the Biotechnology industry, Gilead Sciences Inc. has a higher P/E ratio of 1002.11. Shareholders might be inclined to think that Gilead Sciences Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback